CD8A and neoplasm: For the distant tumor, the percentage of CD8+ T cells in the total tumor cells increased in Hf12-DBA-mediated RT plus anti-PD-L1 treatment group (2.04 ± 1.24%) compared to Hf12-DBA-mediated RT group (1.21 ± 0.48%) and PBS control group (1.20 ± 0.20%) (Fig. 6c).